top of page
Cancer Treatment
Access to lifesaving treatments is blocked for the sickest patients.
These patients can't wait. Compassionate Access is establishing the infrastructure to turn cancer patients who fail treatments into survivors.
FDA approval is too slow, insurers are failing to cover the new tests and treatments, and science has far outpaced our physicians ability to keep up with the expanding options.
Recognizing that every treatment episode provides important information, it's time to enable all oncology practices to combine direct care and research, harvesting the data from every episode. We will create a continuous loop of personalized care supported by outcomes and analytics to create Real World Evidence.
Why this matters
For patients with cancer, rare diseases, or rapidly progressing conditions, time is everything. Yet current research models aren’t built for urgency or individuality. Conventional drug development and clinical trials take years, cost millions, and only serve the majority, not the one patient.
Continuous learning accelerates uptake on how to provide the best care, whether it's for an individual or a cohort, matching patients with interventions that work for them. Standard trials eliminate a patient’s right to choose. Rather than ignoring the patients right to choose, integrating care and research makes the patient’s voice heard, returning hope.
Right now, there’s no easy way for patients or clinicians to initiate and manage research together. Compassionate Access is launching an open registry supported by CRO-LITE, the technology platform and tools that collect data from every treatment as Real World Data, building knowledge to accelerate change.
bottom of page